Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q2 2022 · 10-Q
Revenue$771.30M$771.30M+6.6% vs Q2 2021 Net Income$188.50M$188.50M+0.6% vs Q2 2021 EPS Diluted$2.48$2.48+0.4% vs Q2 2021 Gross Profit$321,500,000+2.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flowderived$173,100,000+19.9% Free Cash Flowderived$107,000,000+22.3% Margins · derivedGross margin41.7%−1.9 pt vs Q2 2021
Operating margin29.6%+0.4 pt vs Q2 2021
Net margin24.4%−1.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Jul 28, 2022 · 28 d after period end